Oculis (NASDAQ:OCS) Shares Gap Down – What’s Next?

Oculis Holding AG (NASDAQ:OCS) gapped down prior to trading on Friday . The stock had previously closed at $15.95, but opened at $15.60. Oculis shares last traded at $15.70, with a volume of 3,088 shares changing hands.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $30.00 price target on shares of Oculis in a research report on Wednesday. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Oculis presently has a consensus rating of “Buy” and a consensus price target of $29.20.

Oculis Price Performance

The company has a fifty day moving average price of $12.89 and a two-hundred day moving average price of $12.20. The firm has a market capitalization of $644.42 million, a price-to-earnings ratio of -8.96 and a beta of 0.30. The company has a quick ratio of 5.27, a current ratio of 5.27 and a debt-to-equity ratio of 0.01.

Oculis (NASDAQ:OCS) last posted its quarterly earnings data on Tuesday, August 27th. The company reported ($0.56) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.13). Oculis had a negative net margin of 7,679.05% and a negative return on equity of 61.33%. The business had revenue of $0.27 million during the quarter, compared to analyst estimates of $0.28 million. On average, equities research analysts expect that Oculis Holding AG will post -2.19 EPS for the current fiscal year.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.